drugset / Trial / NCT03997123
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Timeline
- Start
- 2019-06-25
- Primary completion
- 2026-03-16
- Completion
- 2026-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capivasertib | Small molecule | 400 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |